HUGIN ROBERT J
Known title: DirectorCIK: 0001232505
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
Biohaven signs $100M deal with Ono for IgG degraders. Biohaven has entered a strategic licensing agreement with Ono Pharma for its IgG degrader technology in Japan and select Asian regions. The deal includes up to $100 million in near-term payments, with $80 million paid upfront. This move expands the company's presence in Asia and supports its lead candidate, BHV-1300, which is currently in Phase 3 trials for Graves' disease.
Transaction History
| CB | ▲ Buy | Grant | 1,135 | — | 5/21/2026 | View on chart |
| CB | ▲ Buy | Grant | 1,284 | — | 5/15/2025 | View on chart |
| CB | ▲ Buy | Grant | 1,227 | — | 5/16/2024 | View on chart |
| CB | ▲ Buy | Grant | 1,634 | — | 5/17/2023 | View on chart |
| BHVN | ▲ Buy | Option Exercise | 4,119 | $20K | 10/3/2022 | View on chart |
| BHVN | ▼ Sell | Tax Withholding | 3,263 | $24K | 10/3/2022 | View on chart |
| BHVN | ▲ Buy | Option Exercise | 5,998 | $21K | 10/3/2022 | View on chart |
| BHVN | ▼ Sell | Other | 1,708 | $0 | 10/3/2022 | View on chart |
| BHVN | ▲ Buy | Option Exercise | 9,474 | $32K | 10/3/2022 | View on chart |
| BHVN | ▼ Sell | Other | 1,450 | $0 | 10/3/2022 | View on chart |
| CB | ▲ Buy | Grant | 1,594 | — | 5/19/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Chubb (CB) Q3 Earnings Outlook: Potential Beat Amid Guidance Concerns
Analysts note that Chubb is expected to post earnings above consensus estimates for the third quarter, driven by strong underwriting results and investment income. At the same time, a recent note points to softer EPS guidance and a new fee initiative that could temper optimism. The mixed signals suggest the upcoming report will be closely watched.
Chubb (CB) Q3 Earnings Outlook: Potential Beat Amid Guidance Concerns. Analysts note that Chubb is expected to post earnings above consensus estimates for the third quarter, driven by strong underwriting results and investment income. At the same time, a recent note points to softer EPS guidance and a new fee initiative that could temper optimism. The mixed signals suggest the upcoming report will be closely watched.